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stem cells (iPSC) by treatment with members of
TGF-beta family give rise to osteoblasts
differentiation and form bone in vivo
Feng Li1 and Christopher Niyibizi1,2*Abstract
Background: Induced pluripotent stem cells (iPSC) are generated by reprogramming somatic cells into embryonic
like state (ESC) using defined factors. There is great interest in these cells because of their potential for application
in regenerative medicine.
Results: iPSC reprogrammed from murine tail tip fibroblasts were exposed to retinoic acid alone (RA) or in
combination with TGF-β1 and 3, basic fibroblast growth factor (bFGF) or bone morphogenetic protein 2 (BMP-2).
The resulting cells expressed selected putative mesenchymal stem cells (MSCs) markers; differentiated toward
osteoblasts and adipocytic cell lineages in vitro at varying degrees. TGF-beta1 and 3 derived-cells possessed higher
potential to give rise to osteoblasts than bFGF or BMP-2 derived-cells while BMP-2 derived cells exhibited a higher
potential to differentiate toward adipocytic lineage. TGF-β1 in combination with RA derived-cells seeded onto HA/
TCP ceramics and implanted in mice deposited typical bone. Immunofluorescence staining for bone specific
proteins in cell seeded scaffolds tissue sections confirmed differentiation of the cells into osteoblasts in vivo.
Conclusions: The results demonstrate that TGF-beta family of proteins could potentially be used to generate
murine iPSC derived-cells with potential for osteoblasts differentiation and bone formation in vivo and thus for
application in musculoskeletal tissue repair and regeneration.
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Induced pluripotent stem cells (iPSC) have generated
hope and excitement because of the potential they pos-
sess in regenerative medicine. Since the discovery by
Yamanaka and colleagues that somatic cells can be re-
programmed to embryonic like state (ESC), numerous
reports have emerged focusing on methods to generate
them efficiently and safely for future clinical applications
[1-7]. Some progress has been made toward develop-
ment of techniques for generating safer iPSC; for* Correspondence: cniyibizi@psu.edu
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reproduction in any medium, provided the orexample; generation of virus free iPSC, thus avoiding po-
tential of viral effects on tumor formation, use of protein
factors to reprogram somatic cells and reprogramming
without using oncogenic factors [5-11]. In addition, effi-
ciencies in reprogramming somatic cells have improved
[12-15]. Although more work is still needed to get iPSC
closer to clinical application, it is also critical to begin to
understand factors that play a role in directing differenti-
ation of iPSC to various cell lineages prior to clinical ap-
plication. In this regard, several studies focusing on
methods to direct iPSC to specific cell lineages are active
areas of investigation [16-19]. These approaches emulate
methods developed for directing ESC to various lineages
[20-22]. Most studies have focused on directing ESC
or iPSC to hematopoietic and or neural cells lineages
[16-19]. As a proof of concept, iPSC were generatedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lowed by correction of the sickle cell defect. iPSC with
the corrected gene were then directed to hematopoietic
cell lineage and given back to the somatic cell donor [18].
This proof of concept demonstrated that it was possible
to direct iPSC to hematopoietic lineage efficiently at least
for murine iPSC.
Directing human ESC or iPSC to neural lineages has
also gained some success [17,20,23,24]; Wernig and col-
leagues showed that iPS-cell-derived dopaminergic neu-
rons could alleviate the disease phenotype in a rat model
of Parkinson’s disease [17]. Differentiation of human em-
bryonic stem cells (hESC) and or human induced pluri-
potent stem cells (hiPSC) to mesenchymal cell lineage
have also been reported [25-28]. iPSC were directed to
MSCs differentiation and cells were then sorted based
on CD24 and CD105 surface antigen expression. Sorted
cells were demonstrated to exhibit MSCs characteristics
and gave rise to adipocytes, chondrocytes and osteogenic
lineage [25]. Differentiated iPSC were also shown to alle-
viate ischemia in a mouse model. These data showed
that iPSC have potential to give rise to cells of mesen-
chymal lineage, this approach involved cell sorting which
is inefficient for clinical application. In addition, this has
been successful in human iPS derived cells. Differences
between mouse ESC and iPSC have been noted; methods
used for differentiation of human ESC or iPSC to spe-
cific lineages may not apply to mouse ESC or iPSC.
Directing mouse ESC or iPSC specifically to osteoblasts
lineage and bone formation in vivo has presented a
challenge. Previous reports showed that murine iPSC
could be induced to osteoblasts differentiation and bone
formation; however; Bilousova et al. used retinoic acidFigure 1 Embryoid bodies generated from murine iPSC and morphol
growth factors. (A) EBs derived from murine iPSC (B) iPSC-cells derived by
RA (D) iPSC-cells derived by exposure to TGF-beta1 and RA (E) iPSC-cells d
exposure to BMP-2 and RA. The round cells within each preparation proba
population are outlined in the text in materials and methods section. Origialone for derivation of cells from murine iPSC that
formed calcified structures in scaffolds in vitro and
in vivo [29]. Morphology of the derived cells using this
approach was however not indicated. Jukes et al indi-
cated that, for murine ESC to make bone in vivo, a
cartilage template is a necessity [30]. Although this ap-
proach demonstrated clear bone formation in vivo, it is a
multistep process and does not directly generate MSCs
like cells from iPS. Nevertheless, this approach clearly
demonstrated that murine ESC can be manipulated to
make bone in vivo.
We report here that cells derived from murine iPSC
by treatment with TGF-beta family of proteins specific-
ally TGF-beta 1 and 3 have potential to give rise to cells
that display osteoblasts characteristics in vitro and
in vivo.
Results
Figure 1 shows EBs and morphological appearance of
the cells derived from them by incubation in a medium
supplemented with b-FGF, TGF-beta1, TGF-beta3 and
or BMP-2 in combination with RA or RA alone. The
iPSC-derived cells using the above growth factor treat-
ments displayed fibroblastic morphologies (Figure 1).
TGF-beta 1 and 3 derived cells contained a population
of cells with spindle shaped morphology characteristic of
MSCs. Cells derived by RA alone treatment also con-
tained cells with a spindle morphology but there were
also more cells with rounded morphology when com-
pared to TGF-beta 1 or 3 population. Cells derived by
FGF-RA or BMP-2 comprised cells with flattened
morphologies as well as cells with rounded morpholo-
gies. Nevertheless all cell populations did not appearogical appearance of iPSC-cells derived by treatment with various
exposure to RA alone (C) iPSC-cells derived by exposure to bFGF and
erived by exposure to TGF-beta3 and RA (F) iPSC-cells derived by
bly represent undifferentiated cells. Details for generation of each cell
nal magnifications 200X.
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cell population present within the preparations. We did
not quantitate ratios of subpopulation within each prep-
aration, the goal was to generate cells that were enriched
in a population with a higher potential to differentiate
toward osteoblastic lineage.
We did not perform gene expression analysis to dem-
onstrate loss of multipotency markers by each of the cell
population generated by different treatments. Previously,
we demonstrated that cells derived from iPSCs (EBs) by
treatment with TGF-beta 1or RA alone lost expression
of multipotency markers [31], based on these previous
data, it was concluded that these cell populations were
devoid of multipotency markers.
To further characterize iPSC-derived cells, expression
of surface antigens attributed to MSCs was examined by
FACS analysis. Expression profiles of the selected surface
markers by each of the growth factor derived cells are
shown in Figure 2. All cell populations derived by vari-
ous treatments contained cells that expressed CD13,
CD34, CD44, CD73, CD105 and CD 117 at varying
degrees. Basic fibroblast growth factor (bFGF) and RA
alone derived cells comprised a population expressing
high levels of CD34 suggesting that they were enriched
in cells of hematopoietic lineage. TGF-beta1 and 3-
derived cell populations contained a population of cells
expressing high levels of CD73 and less of cells expres-
sing CD34 (Figure 2). All cell populations derived by
various treatments, contained a population of cells
expressing CD105 at very low levels. In TGF-beta1 and
3 derived cells, only 10% of the cells were CD105 posi-
tive. It was not determined whether the CD105 cellsFigure 2 FACS profile of selected surface antigens by iPSC-cells deriv
surface antigens that was assessed is indicated in the figure. bFG- derived
TGF-β1 and 3-derived cells were enriched in populations expressing CD13,
enriched in a population of cells expressing high levels of CD73 and CD44were also CD73 positive. CD73 is one of the markers
attributed to MSCs and has been used previously to sort
cells from hESC with potential to give rise to cells of
mesenchymal lineage [32]. Markers expressed by iPSC
(EBs) that were not manipulated were not determined,
RA derived cells were used as controls in these experi-
ments and this is a common protocol used for ES and
iPS cell differentiation. As indicated above these cells
expressed lower levels of markers attributed to MSCs
when compared to those derived by other treatments ex-
cept bFGF (Figure 2). Because of lack of specific marker
for identifying MSCs; the relationship of CD 73 expres-
sing cells to MSCs could not be verified.
Next, we examined differentiation of the cell popula-
tions toward osteogenic and adipogenic lineages. The
results showed that in all treatment groups, the cells were
capable of differentiating toward osteogenic lineage but at
varying degrees. Retinoic acid alone and or bFG-derived
cells exhibited reduced capacity to differentiate toward
osteogenic lineage as demonstrated by the quantitation of
Alizarin Red deposits in osteogenic differentiating cultures
(Figure 3A and B). TGF-beta1- derived cell populations
exhibited higher differentiation ability toward osteogenic
lineage than the other cell populations generated by other
treatments. The cell population derived by treating iPSC
with BMP-2 exhibited higher ability to differentiate to-
ward adipogenetic lineage (Figure 3D and E). These data
suggest that TGF-beta1 and BMP-2 have distinct activities
toward iPSC differentiation. Because iPSC-TGF-beta3-
cells had similar differentiation capabilities as TGF-beta1-
cells, data is only shown for TGF-beta1 treatment cell
populations. Retinoic acid derived cells were used ased using different factors. The level of expression for each of the
cells comprise a population expressing high levels of CD34 and CD44.
CD73 and less CD105. IPSC-cells-derived by exposure to BMP-2 were
but less CD105. P < 0.05.
Figure 3 In vitro osteogenic, adipogenic differentiation and gene expression of iPSC-cells generated using different factors. (A)
Osteogenic differentiation of iPSC-cells-derived by exposure to RA alone; bFGF-RA, TGF-beta1-RA and TGF-beta3-RA. (B) quantitation of Alizarin
Red deposition by each of the cell population. iPSC-TGF-beta1-RA-derived cells deposited more calcium based on Alizarin Red quantitation. (C)
Expression of osteoblasts associated genes by differentiating cell populations. iPSC-BMP-2-RA cells express lower levels of osteogenic genes; (D)
Adipocytic differentiation of iPSC- RA-cells, bFGF-RA-cells, TGF-beta1,3-RA-cells and BMP-2-RA-cells as assessed by Oil Red O staining. (D) All cells
show adipogenic differentiation but BMP-2 derived cells show higher adipogenesis. (E) Quantitation of adipogenic differentiation based on Oil
Red O deposition; all cells show adipogenic differentiation but BMP-2 derived cells show higher adipogenesis. (F) Semi quantitative PCR of
osteoblasts and adipocytes associated genes expression by the iPSC-cells respectively. BMP-2-derived iPSC-cells showed least expression of
osteoblasts associated genes but higher adipogenic differentiation markers. P <0.05. NM= normal medium, OM= osteogenic medium, AM=
adipogenic medium. OSX= Osterix, OPN= osteopontin, OCN= Osteocalcin..
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sion by cells generated by various treatments.
Gene expression profile of osteogenic markers con-
firmed differentiation data. At day 28 following induction
of differentiation, all cell populations expressed Runx2,
osterix (OSX), osteopontin (OPN) and osteocalcin
(OCN) (Figure 3C). Semi quantitative RT-PCR results
indicated that BMP-2 derived cells expressed lower levels
of osteogenic markers than the cells derived by TGF-
beta1; retinoic acid alone and or bFGF cell populations
(Figure 3C). In addition, we previously demonstrated
that iPSC not treated with supplements did not express
osteoblasts related markers [31]. These data are in agree-
ment with Alizarin Red staining results shown in
Figure 3A and B. Expression of adipocyte related genes
confirmed adipogenic differentiation of the cells gener-
ated by treatment of iPSC with various growth factors
(Figure 3F).
To determine whether the cells had the ability to make
bone in vivo, they were seeded onto HA/TCP scaffolds
and implanted onto the backs of SCID mice. Because
cells derived by TGF-beta1 treatment showed higher dif-
ferentiation ability in vitro toward osteogenic lineage,
they were assessed for bone formation in ceramics and
compared to cells derived by RA alone treatment. Ana-
lysis of tissue sections at 5 weeks after implantation,showed that both cell populations were capable of deposit-
ing bone in ceramics; however, TGF-beta1 derived cells
appeared to deposit more bone with evidence of blood
vessels (Figure 4B and C). The newly deposited bone con-
tained surface lining osteoblasts and osteocytes embedded
in bone as indicated by yellow and green arrows respect-
ively (Figure 4B,C). HA/TCP ceramics not seeded with
cells did not show any bone formation (Figure 4A). These
data demonstrated that iPSC derived cells by TGF-β1
treatment exhibit potential to deposit bone in vivo.
Collagen deposition by the cells in ceramics was
assessed by trichrome staining; HA/TCP ceramics not
seeded with cells showed absence of collagen staining as
expected (Figure 4D). Ceramics seeded with cell popula-
tions from RA alone or in combination with TGF-beta1
treatments revealed staining in areas of bone deposition
(Figure 4E,F). Examination of ceramic tissue sections of
TGF-beta1 treated iPSC-derived cells indicated presence
of more bone than RA treated derived cells (Figure 4E,F).
Osteoblasts and osteocytes are indicated by yellow arrows.
These data clearly demonstrate that iPSC-derived cells by
TGF-beta1 in combination with RA treatment synthesize
and deposit organic bone matrix and form bone in vivo.
From 6 ceramics implanted with the cells, 2 were found
to contain few teratomas suggesting that in some cases,
there were some residual cells with multipotency within
Figure 4 Histological analysis of bone formation and trichrome staining in ceramic scaffolds seeded with iPSC-TGF-beta1-RA-cell or
iPSC-RA-cells and implanted in mice. (A) Tissue section of a ceramic scaffold not seeded with cells; no bone formation is evident, only the
ceramic scaffold (HA/TCP) is present. (B) Tissue section of a ceramic scaffold seeded with iPSC-RA-cells shows fewer islands of bone formation
scattered in the scaffold. (C) Tissue section of a ceramic scaffold seeded with iPSC-TGF-beta1-RA-cells show many large islands of bone within the
scaffold. (D) Trichrome staining in a tissue section of a ceramic scaffold implanted without cells and stained with trichrome. There is no staining for
collagen, a major protein component of bone indicating absence of bone in this scaffold. (E) Ceramic scaffold implanted with iPSC-RA-cells and
stained with trichrome; staining for collagen (blue) is present within the thin island of bone within the scaffold confirming H and E staining for
presence of bone. (F) Ceramic scaffold seeded with iPSC-TGF-beta1-RA-cells. iPSC-TGF-beta1- RA-cells deposited more bone in scaffolds than RA
alone derived cells based on histological observations of the bone size within the ceramics. Trichrome staining in the bone islands is evident
confirming presence of bone matrix within the islands. Osteoblasts lining bone surfaces are indicated by yellow arrows; osteocytes are indicated by
green arrows and blood vessels within the newly made bone are indicated by black arrows. Osteoblasts and osteocytes were identified by their
location within bone. Cells lining the surface were presumed to be osteoblasts and cells embedded in bone were assumed to represent osteocytes.
Scale bar 200 μm.
Figure 5 Immunofluorescence staining for osteocalcin in tissue sections of murine cortical bone and in ceramics seeded with iPSC-
TGF-beta1-RA-cells. (A) DAPI staining in a tissue section from a murine cortical bone (B) Immunofluorescence staining for osteocalcin in
tissue section of cortical bone (C) Immunofluorescence staining in a tissue section in which primary antibody was omitted. (D) DAPI staining in a
tissue section from a ceramic seeded with iPSC-TGF-beta1-RA-cells; (E) Immunofluorescence staining of osteocalcin in a tissue section of a
ceramic scaffold seeded with iPSC-TGF-beta1-RA-cells; (F) Overlay image of D and E showing osteocalcin expressing cells colocalizing with DAPI
staining cells. Original magnifications 200X. The data confirm that iPSC-cells derived by TGF-beta1 in combination with RA differentiated into
osteoblats in vivo and deposited bone.
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from iPS by TGF-beta 1 treatment were devoid of cells
capable of making teratomas.
To confirm that TGF-beta1 or RA alone treatments
derived cells differentiated into osteoblasts and were re-
sponsible for the bone that was deposited in ceramics, im-
munofluorescence staining to colocalize donor cells with
osteoblasts-specific proteins was carried out. Tissue sec-
tions made from demineralized ceramics seeded with
iPSC-cells derived by RA alone or in combination with
TGF-beta1 were examined for osteocalcin and dentin
matrix protein 1 (DMP-1) synthesis. Tissue sections made
from mouse cortical bone were used as positive controls;
ceramic scaffolds not seeded with cells were negative con-
trols. Figure 5 illustrates immunofluorescence staining for
osteocalcin in a murine cortical bone tissue section and
in ceramics retrieved from recipient mice; FITC secon
dary antibodies were used for visualization (Figure 5).
Figure 5A shows DAPI staining in a tissue section of a
mouse cortical bone; Figure 5B is immunofluorescence
staining for osteocalcin in the equivalent tissue section of
the cortical bone. Immunofluorescence staining for osteo-
calcin is shown in green (Figure 5B). Figure 5C shows
immunofluorescence staining in a tissue section in which
primary antibody was omitted but processed similarly as
in sections shown in Figure 5A and B (Figure 5).
Figure 5D is DAPI staining of the tissue sections made
from ceramics seeded with iPSC-TGF-beta1-RA-cells.
Figure 5E is an imunofluorescence staining for osteocalcin
in the ceramics seeded with iPSC-TGF-beta1-RA derived
cells. Figure 5F is an overlay image of D and E indicatingFigure 6 Immunofluorescence staining for DMP1 in tissue sections o
cortical bone. (A) DAPI staining in a tissue section from a murine cortic
section of cortical bone; (C) Immunofluorescence staining in a tissue sec
a tissue section from a ceramic scaffold seeded with iPSC-TGF-beta1-RA-
a ceramic scaffold seeded with iPSC-TGF-beta1-RA-cells; (F) Overlay imag
DAPI staining cells. Original magnifications 200X. The data confirm that i
ceramic scaffolds.that cells seen in the ceramics synthesized osteocalcin thus
confirming that the cells differentiated into osteoblasts
in vivo. These data support the conclusion that iPSC-
TGF-beta1-RA-cells differentiate into osteoblasts and de-
posit bone in vivo.
Dentin matrix protein 1 (DMP1) is an extracellular
matrix protein synthesized by osteocytes [33,34]. We
used immunofluorescence staining for DMP-1 to deter-
mine whether iPSC-derived cells proceeded to osteocytes
differentiation in ceramics. Figure 6 shows the results of
immunofluorescence staining for DMP1 in cortical bone
and in ceramics seeded with iPSC-cells derived by TGF-
beta1 treatment. Figure 6A is DAPI staining for cells in
a tissue section made from a mouse compact bone
which was used as a positive control; Figure 6B is an im-
munofluorescence staining for DMP1 in murine com-
pact bone and Figure 6C is a control tissue section in
which primary antibody was omitted. Figure 6D and E
show DAPI and immunofluorescence staining for DMP1
in ceramics seeded with iPSC-TGF-beta1-RA-cells re-
spectively. Figure 6F is an overlay image of 6D and
6E images. Because DMP1 is a secreted protein, DAPI
staining in Figure 6D did not seem to align with DMP1
expressing cells in Figure 6E; nevertheless DMP1 stain-
ing was evident in the ceramics implanted with TGF-β1
iPSC-RA-cells. These data together with data presented
in Figure 5, clearly confirm that iPSC-TGF-beta1-RA-
derived cells differentiate into osteoblasts and osteocytes
in vivo and deposit bone in ceramics implanted in SCID
mice. Taken together, these data imply that TGF-beta 1
is the most effective in generating cells from iPSC withf ceramic scaffolds seeded with iPSC-TGF-beta1-RA-cells and
al bone; (B) Immunofluorescence staining for DMP1 in a tissue
tion in which primary antibody was omitted; (D) DAPI staining in
cells; (E) Immunofluorescence staining of DMP1 in a tissue section of
e of D and E indicating that DMP1 expressing cells colocalize with
PSC-TGF-beta1-RA-cells proceed to osteocyte differentiation in
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bone in vivo in comparison to other factors assessed in
this study.Discussion
Induced pluripotent stem cells have generated excite-
ment because of potential they possess for generating
patient specific embryonic like stem cells [1-3,5]. There
are many hurdles to overcome prior to clinical applica-
tion of these cells; for example production of safer iPSC
that would be suitable for clinical application and meth-
ods to direct them to specific lineages to avoid tumor
formation. Some progress has been made toward gener-
ating safer iPSCs; for example, production of iPSC with-
out use of viruses, use of protein and chemical factors to
reprogram somatic cells [5-11]. In addition, efficiency in
generating the cells has improved. Methods to direct
iPSC or ESC to a limited number of specific lineages
have also been reported [12-15], but this remains a chal-
lenge. Our interest is to direct murine iPSC to cells cap-
able of differentiating into osteoblasts; this remains a
challenging task [35,36]. Human and mouse iPSC and
ESC display different responses to factors that control
their differentiation to various cell lineages [37]. Differ-
entiation protocols for human iPSC or ESC may not
apply to murine cells. In the present report, we examined
members of TGF-beta family for enhancing generation of
cells that exhibit potential to give rise to osteoblasts and
bone formation in vivo. The results showed that TGF-β1
and 3 in combination with RA were more effective in
generating cells from iPSC with ability to give rise to
osteoblasts and make bone in ceramics implanted in
mice. Interestingly, although BMP-2 is a member of
TGF-beta 1 family, iPSC-BMP-2-RA-derived cells exhib-
ited a higher ability to adipocyte differentiation in vitro.
These findings suggested that TGF-beta1 and BMP-2 dis-
play distinct activities toward iPSCs.
Several studies have demonstrated that BMPs play
important roles in stem cell differentiation to various
cell lineages [36,38,39]. BMP-2 has been shown to have
a strong effect in inducing MSCs differentiation toward
osteogenic and chondrogenic lineages under specific
conditions [40]. Previous reports have shown evidence
for participation of BMP2/4 in the commitment of
pluripotent stem cells to the adipocyte lineage [41-44].
Specifically, exposure of BMP-2/BMP-4 to C3H10T1/2
cell line established from 14- to 17-day-old C3H mouse
embryos induced these cells to commit toward adipocy-
tic lineage [45-47]. These findings are in agreement
with the present findings in which exposure of iPSC
derived cells to BMP-2 induced their commitment to
adipocyte differentiation. Members of the TGF-beta
superfamily have been shown to play a role in inductionof mesoderm in Xenopus, zebrafish, chicken and mouse
[48,49]. TGF-beta1 was shown to promote early chon-
drogenesis during the embryonic endochondral ossifi-
cation process [50]. Present findings suggest that TGF-
beta1 may be playing a role of enhancing production of
putative bone progenitors from iPSC at least in murine
iPSC.
Few reports have shown bone formation in vivo by
murine ESC-derived progenitors [30,51]. One report
demonstrated that for murine ESC to make bone in vivo
a cartilage template is required [30]. In another report
RA was used to generate cells from murine iPSC that
were shown to form calcified structures in vitro and
in vivo [29]. The present report has shown that exposure
of iPSC derived- EBs to TGF-β family of proteins in
presence of RA enhanced production of cells with ability
to differentiate toward osteoblastic lineage. In addition,
TGF-beta1 derived cells formed larger bone surfaces
than RA alone derived cells as determined by examin-
ation of tissue sections made from scaffolds seeded with
RA alone and TGF-beta1-RA derived cells. The results
suggest that use of TGF-beta-family of proteins may en-
hance generation of cells from iPS cells at least in mur-
ine that have potential to make bone in vivo. The data
reported here showed that these cells were enriched in a
population expressing CD73; in the same cell popula-
tion, 10% of the cells expressed CD105. Expression of
low CD105 and CD90 by murine iPSC derived cells were
also shown previously in cells derived by RA treatment
alone [29]. The relationship of these cells to MSCs is not
clear because there is no one specific marker for identi-
fying MSCs. Previous reports on generating cells with
MSCs characteristics from hESC have used CD73 anti-
gen to sort for cells with MSCs characteristics. The
results showed that cells sorted based on this antigen
were capable of giving rise to osteoblasts, adipocytes and
chondrocytes in vitro [32]. Because these were human
cells, these data cannot be extrapolated to murine cells.Conclusion
Taken together, the present findings showed that iPSC-
derived cells by exposure of iPSC to TGF-beta1 or 3 in
presence of RA enhances production of cells with ability
to give rise to cells that deposit bone in ceramic scaffolds
implanted in SCID mice. The results suggest that TGF-
beta1 or 3 in presence of RA may be used to generate
progenitors from murine iPSC that have potential to
make bone. Although these results are of interest, they
may not be applicable to human iPSCs. The data are
however, of interest because they provide opportunities
for investigating application of iPSCs in bone regener-
ation using murine models.
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Generation of murine induced pluripotent stem cells
(iPSC)
Stocks of murine iPSC generated previously by repro-
gramming tail tip fibroblasts (TTF) were used in the
present studies. Methods for their production and
characterization were described previously [31]. The
iPSC generated from TTF were cultured on irradiated
murine embryonic fibroblasts (MEFs) feeders in stand-
ard ES medium as described [31].
Embryoid body formation (EBs) and generation of MSCs-
like cells
iPSC colonies were trypsinized and transferred to ultra-
low attachment culture dishes (Corning, Corning, NY)
to generate embyroid bodies (EBs). The EBs were main-
tained in ES medium without leukemia inhibitory factor
(LIF) for 3 days. After 3 days of suspension culture, EBs
were incubated in ES culture medium supplemented
with 40 ng/ml retinoic acid (RA) for two days followed
by two day incubation in a medium supplemented with
either 10 ng/ml TGF-beta1, 10 ng/ml TGF-β3, 10 ng/ml
bFGF or100 ng/ml BMP-2 for 3 days. Following incuba-
tion in this medium, cells were transferred onto 0.1%
gelatin-coated plates and incubated in DMEM supple-
mented with 10% FBS and 50 μg/ml of ascorbic acid.
When the cells were near confluent, they were trypsi-
nized and replated onto 0.1% gelatin-coated tissue cul-
ture dishes and incubated in the same medium as above.
After two passages, the derived cells were used for FACS
analysis and osteogenic and adipogenic differentiation
in vitro and in vivo.
FACS analysis
The iPSC-derived EBs differentiated by retinoic acid and
or various growth factor treatments were harvested and
incubated in a buffer containing antibodies to selected
putative MSCs surface antigens. Antibodies used for
FACS analysis were phycoerythrin (PE) conjugated to
anti-CD13, anti-CD34, anti-CD44, anti-CD45, anti-
CD73, anti-CD90, anti-CD117, and unconjugated anti-
bodies against CD105 (BD Biosciences, San Diego, CA).
Methods described previously were used for preparation
of the cells for FACS analysis [52]. In brief, a total of
2 × 105 cells from different treatments were resuspended
in 200 μl of Dulbecco’s PBS containing 2% FBS and
0.01% NaN3 and incubated for 30 minutes at 4°C with
phycoerythrin (PE)-conjugated antibodies to surface anti-
gens for analysis. This was followed by followed by
PE-conjugated secondary antibodies (Santa Cruz Bio-
technology Inc., Santa Cruz, CA). The proper isotype-
identical Igs served as controls. After staining, the cells
were fixed in 2% paraformaldehyde, and quantitative
FACS analysis was performed on a FACStar flowcytometer (BD Biosciences, San Diego, CA). Each sam-
ple was tested three times.
Osteogenic differentiation and bone formation
The iPSC-derived cells by different growth factor treat-
ments were trypsinized, plated in six-well plates, and cul-
tured in an osteogenic medium as described previously
[53,54]. After 28 days of incubation, cells were stained in
Alizarin Red S solution and examined under a light
microscope. Alizarin deposits were extracted with 10%
acetic acid and used for quantification of mineralization.
Adipogenic differentiation
For adipogenic differentiation, iPSC-derived cells were
plated in 12 well plates in adipogenic medium at a cell
density of 5 × 103 cells per well. The adipogenic medium
was composed of DMEM with high glucose supplemented
with 10% FBS, 0.1 mM indomethacin, 0.5 mM isobutyl-
methylxanthine (Sigma-Aldrich), and 10-6 M dexametha-
sone. The media were replaced every 3 days for 28 days.
Adipogenic differentiation was assessed by Oil Red O
staining at 3 weeks after initial adipogenic induction. For
Oil Red O staining, the cells were rinsed in PBS and fixed
in 10% formalin followed by incubation of the cells in 2%
(wt/vol) Oil Red O reagent for 5 minutes at room
temperature, examined under light microscope and
photographed. The cells were suspended in 0.5 ml of iso-
propanol to extract Oil Red O for quantification of the
level of adipogenic differentiation.
In vivo bone formation
The Institutional Animal Care and Use Committee of
Penn State University College of Medicine approved all
animal procedures; all animal experiments were carried
out following the approved protocol. Retinoic acid alone
or in combination with TGF-beta1 iPSC derived cells
were trypsinized and seeded onto HA/TCP ceramic scaf-
folds at 5 × 106 cells/mL. Cells were allowed to attach to
the ceramics for 2 h at 37°C prior to implantation in ani-
mals. Cell seeded Scaffolds were implanted subcutane-
ously onto the backs of thymic SCID mice. Five weeks
after implantation; animals were sacrificed and the scaf-
folds were harvested.
Histological analysis
For histological analysis, methods described previously
were used [53]. Briefly, HA/TCP ceramic scaffolds
seeded or not seeded with iPSC-derived cells and
retrieved from recipient mice were fixed in freshly pre-
pared 4% paraformaldehyde in PBS, containing 10% su-
crose. Following fixation, the scaffolds were decalcified
and embedded in paraffin. Ten micron tissue sections
were cut, prepared for histological analysis and stained
with H and E. Tissue sections were also stained by a
Li and Niyibizi BMC Cell Biology 2012, 13:35 Page 9 of 10
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collagen synthesis [55].
Immunofluorescence for Osteocalcin and Dentin matrix
protein
Cryosections prepared from the ceramic scaffolds seeded
or not seeded with cells were retrieved from recipient
mice at 5 weeks following implantation. Tissue sections
were fixed in cold acetone for 5 minutes and treated
with 10% goat serum, followed by treatment with a poly-
clonal antibody specific for Osteocalcin (1:20 Millipore)
or DMP-1 (1:50 RDI). Tissue sections made from murine
cortical bone were treated similarly. For visualization,
sections were treated with the secondary rabbit anti-rat
antibodies conjugated with either FITC (Millipore) or
Rhodamine (Santa Cruz, Santa Cruz CA) at a concentra-
tion of 1:1000 and 1:500 respectively.
Gene expression analysis
Gene expression analysis of osteogenic and adipogenic
associated genes were performed as described previously
[53]. Triplicate PCR reactions were carried out.
Statistical analysis
Statistical analysis was carried out using SPSSW software
(SPSS, Chicago, IL). One-way ANOVA with a Tukey’s
post-hoc analysis was used to evaluate for differences in
growth factors treated and untreated samples for osteo-
genic and adipogenic differentiation and marker expres-
sion. Significance was set at P < 0.05.
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